We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
KemPharm Inc. (pipeline of prodrugs for multiple CNS indications) netted $23.5mm through the public sale of 8.3mm shares at $3. The company plans to use the proceeds to fund its lead extended-release dexmethylphenidate prodrug candidates for attention deficit hyperactivity disorder (ADHD); an NDA submission for KP415 (anticipated Q1 2019); and the initiation of a pivotal trial for preclinical KP484 (expected to begin next year). Earlier this year, KemPharm's first prodrug--abuse-deterrent Apadaz (benzhydrocodone/acetaminophen) for short-term management of acute pain--was approved by the FDA.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Drug Delivery
Controlled Release
Biotechnology
Drug Discovery Tools
Deal Status
Final
Deal Type
Financing
FOPO
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?